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Abstract
Background: Sensitivity and accuracy are key points when using microarrays to detect alterations
in gene expression under different conditions. Critical to the acquisition of reliable results is the
preparation of the RNA. In the field of virology, when analyzing the host cell's reaction to infection,
the often high representation of viral RNA (vRNA) within total RNA preparations from infected
cells is likely to interfere with microarray analysis. Yet, this effect has not been investigated despite
the many reports that describe gene expression profiling of virus-infected cells using microarrays.
Results: In this study we used coronaviruses as a model to show that vRNA indeed interferes with
microarray analysis, decreasing both sensitivity and accuracy. We also demonstrate that the
removal of vRNA from total RNA samples, by means of virus-specific oligonucleotide capturing,
significantly reduced the number of false-positive hits and increased the sensitivity of the method
as tested on different array platforms.
Conclusion: We therefore recommend the specific removal of vRNA, or of any other abundant
'contaminating' RNAs, from total RNA samples to improve the quality and reliability of microarray
analyses.
Background
In various research fields, microarray analysis is frequently
being used as a tool to analyze alterations of the transcrip-
tome in response to different stimuli. However, this tech-
nology often has serious limitations related to its
sensitivity, specificity and reproducibility [1]. A key step in
the generation of reliable data involves the isolation and
processing of the RNA, since high quality RNA is needed
to obtain accurate results.
In the field of virology, microarrays are often used as a
diagnostic tool to detect the presence of certain viruses
within biological samples or to discover new viruses [2,3].
In addition, microarray analysis is regularly applied to
identify host genes of which the expression is altered
upon virus infection. Whole-genome profiling of virus-
infected cells, in combination with other large-scale, high-
throughput technology, rapidly increases our knowledge
of virus-host interactions and may eventually lead to the
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production of new antivirals [4]. Often these screens are
performed using cultured cells with high doses of virus in
order to infect all the cells present. As most viruses repli-
cate and transcribe their genome very efficiently, the
resulting high levels of viral RNA (vRNA) may be expected
to interfere with the microarray analysis. The potential
interference of vRNA with array procedures is of particular
concern when the vRNAs are polyadenylated, given that
most microarray protocols involve mRNA amplification
using oligo(dT) primers, thereby hence also amplifying
viral mRNAs. This potential problem especially holds true
for RNA viruses, including coronaviruses (CoV), the repli-
cation of which has been shown to result in an exponen-
tial increase in vRNA levels within hours after inoculation
of the cells [5-7].
CoVs are enveloped, positive-stranded RNA viruses and
are well-known pathogens in man and animals. Their rel-
evance has increased significantly with the current surfac-
ing of new human CoVs (HCoVs), such as the severe acute
respiratory syndrome (SARS)-CoV [8], HCoV-NL63 [9],
and HCoV-HKU1 [10]. CoVs replicate exclusively within
the cytoplasm of their target cells, producing a nested set
of subgenomic mRNAs (Fig. 1), which contain identical 5'
and 3' terminal sequences [11]. These mRNAs are tran-
scribed by a discontinuous transcription mechanism; they
acquire a 5' cap structure and become 3' polyadenylated,
which makes them equivalent to host cellular mRNAs
[12]. Gene expression profiling of coronavirus-infected
cells has been performed in several microrarray studies in
order to get more insight in the coronavirus-host interac-
tions that contribute to pathogenesis [7,13-15].
Although large numbers of genes with altered expression
have been identified in virus-infected cells, no report
exists, which addresses to what extent the high levels of
vRNA affect microarray performance. Therefore we inves-
tigated the potentially disturbing effect of vRNA overrep-
resentation on array outcome by using the mouse
hepatitis coronavirus (MHV) as a model and by employ-
ing two different microarray platforms. Our observations
indeed show that the presence of vRNAs in the prepara-
tion interferes quite dramatically with the genechip
assays. Removal of vRNAs from the total RNA pool before
the processing of the RNA for subsequent array hybridiza-
tion drastically decreased the number of false positive hits
for one platform and increased overall sensitivity in both
systems. We conclude that depleting vRNAs from infected
cell total RNA extracts is beneficial for the microarray
analysis not only of cornavirus infection but probably for
many other virus infections as well. In addition, the
approach is likely to be equally advantageous in other cir-
cumstances where 'contaminating' (viral) RNAs constitute
a significant fraction of the target RNA to be processed for
microrarray analysis.
Coronavirus RNA replication strategy Figure 1
Coronavirus RNA replication strategy. MHV-A59 produces a nested set of subgenomic mRNAs (sgRNAs) that all have 
identical 5' and 3' terminal ends. Via discontinuous transcription, during the synthesis of the minus strand, sgRNAs obtain the 5' 
leader sequence fused to a transcriptional regulating sequence (TRS, indicated by the numbered small black boxes), followed by 
a protein-coding region that is flanked at the 3' terminus by an untranslated region (3'UTR) and a polyA-tail (indicated as 
AA(A)n). Note that the nucleocapsid (N) gene is present in all sgRNAs. The three biotinylated oligonucleotides, which are used 
in the vRNA removal procedure and which are complementary to three regions in the viral genome, are indicated by the 
underscores and the letters A, B, and C (see Table 1 for the nucleotide sequences).BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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Results
vRNA interferes with microarray analysis
In order to investigate the potential interference of vRNA
during microarray procedures, we first analyzed in detail
the synthesis of vRNA during the course of an MHV infec-
tion and the subsequent effect of the presence of vRNA on
the mRNA amplification plots. To this end, we infected
LR7 cells with MHV-A59 (MOI = 10) and determined the
amount of vRNA at different time-points p.i. using quan-
titative Taqman RT-PCR. As is shown in Fig. 2A, early in
infection there is an exponential increase of the vRNA lev-
els. The 4 h and 6 h p.i. time-points, which differ approx-
imately 100 fold in their amounts of vRNA, were chosen
for further analysis. Total RNA extracts obtained from
mock- and MHV-infected cells were subjected to the
mRNA amplification protocol, after which the resulting
cRNA was analyzed with the Bioanalyzer. As previously
mentioned, coronaviral RNAs are polyadenylated, and
should therefore also be amplified with the oligo(dT)
primers. Whereas amplification of mRNA of mock- and
MHV-infected cells at 4 h p.i. resulted in similar Bioana-
lyzer profiles, aberrant peaks were observed after amplifi-
cation of the mRNA derived from MHV-infected cells at 6
h p.i. (Fig. 2B). The most abundant peak within the latter
amplification plot corresponded in size with the most
abundant subgenomic RNA of MHV [16], which encodes
the N protein (Fig. 1). Determination of the peak surface
area showed that at least 40% of the amplified mRNA
pool is of viral origin.
Next, microarray experiments were performed to study the
effect of these huge amounts of vRNA present in the target
cRNA samples. First, 70-mer oligonucleotide arrays,
which are routinely used in the Utrecht microarray facil-
ity, were used as proof of principle. As shown in the scatter
plots in Fig. 2C, expression of only few genes was upregu-
lated at 4 h p.i., whereas there appeared to be a dramatic
increase in the number of genes, the expression of which
was upregulated at 6 h p.i. However, quantitative RT-PCR
could not confirm the differential expression of several of
these genes (see Additional file 1; False-positive hits). For
example, the very high level of expression of the Usp2
gene in MHV-infected cells at 6 h p.i., according to the
array analysis, could not be validated by quantitative RT-
PCR. In addition, expression of several other genes, which
were identified as highly upregulated by the array analy-
sis, could not be detected by Taqman RT-PCR both in
infected and mock-infected cells. Interestingly, when the
nucleotide sequences of the oligonucleotides on the
arrays, of these apparently false-positive hits, where com-
pared to the N gene nucleotide sequence, small stretches
(10–15 nucleotides) of identical sequences were observed
(data not shown), substantiating the suggestion of cross-
hybridization of vRNA to specific sequences on the arrays.
Cross-hybridization of vRNA to arrays
The cross-hybridization of vRNAs to the arrays was further
explored by performing a similar experiment as described
above. Only now, the mock- and MHV-infected cells were
treated with ActD, which blocks cellular transcription but
not MHV replication [17,18]. By using this inhibitor of
cellular transcription we were able to discriminate
between genuine upregulation of gene expression and
cross-hybridization. Apparent upregulation of gene
expression in the presence of ActD, is most likely caused
by cross-hybridization of vRNAs to the arrays. Amplifica-
tion of the mRNA obtained from the MHV-infected, ActD-
treated cells again resulted in the appearance of aberrant
peaks, which were not observed in the amplification plots
of the mock-infected cells (Fig. 3A). The subsequent
microarray experiment (Fig. 3B) gave similar results to the
one shown in Fig. 2C. Almost 2000 genes were upregu-
lated under both conditions, indicating that most genes
identified by the array analysis are indeed the result of
cross-hybridization and not of induction of gene expres-
sion (Fig. 3C). Moreover, 2290 genes were specifically
identified in the experiment with ActD. Since viral mRNA
is efficiently replicated and transcribed in the presence of
ActD, while cellular transcription is blocked, the identifi-
cation of these genes probably results from a relative
increase in the amount of vRNA within the target cRNA
samples. Indeed, comparison of the Bioanalyzer profiles
shown in Fig. 3A and Fig. 2B showed that the aberrant
peak is higher after treatment with ActD. Interestingly,
there is also a significant number of genes downregulated
in the absence and presence of ActD, indicating that a
post-transcriptional mRNA decay pathway is induced dur-
ing MHV infection, a phenomenon which we described
recently [7].
Extraction of vRNA from total RNA improves microarray 
analysis
Since the vRNAs appear to affect the array analysis signif-
icantly, we employed a technology to remove these RNAs
from the total RNA pool before processing of the samples
for microarray analysis (i.e. mRNA amplification, labe-
ling, and hybridization). For this purpose, biotinylated
oligonucleotides (27–30 nt in length) complementary to
three regions of the MHV-A59 genomic and subgenomic
RNAs (the 5' leader, N, and 3' UTR region; Fig. 1) were
designed (see Methods for nucleotide sequences). The
same RNA samples as described above were now sub-
jected to the vRNA removal protocol. In short, the RNA
samples were incubated with the MHV-specific oligo's
under stringent hybridization conditions, after which the
captured vRNAs were bound to streptavidin-coated beads,
and removed. Quantitative RT-PCR targeting the viral N
gene, which is present in all MHV-encoded RNAs, demon-
strated that approximately 90% of the vRNAs were
removed by this procedure (data not shown). Amplifica-BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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Microarray analysis of MHV-infected LR7 cells Figure 2
Microarray analysis of MHV-infected LR7 cells. (A) Genomic viral RNA (vRNA) levels in MHV-infected LR7 cells (MOI 
10) were measured by quantitative RT-PCR at the indicated time points. The data are presented as relative vRNA levels. (B) 
Successful amplification of the mRNA within the individual samples was monitored by analyzing the cRNA samples with a Bio-
analyzer (Agilent), according to the manufacturer's instructions. Representative mRNA amplification plots of total RNA sam-
ples obtained from mock- or MHV-infected cells at 4 h and 6 h p.i. are shown. The indicated plots represent the size 
distribution of the total mRNA content present in the samples. The marker peak is indicated by the arrow. Note that the scal-
ing is different between the plots in order to visualize the complete profile. (C) Total RNA was isolated and processed for 
microarray analysis as described in the Methods section. The scatter plots display the average expression values from inde-
pendent dye-swap hybridizations (n = 6) for each gene present on the arrays at the indicated time-points p.i. Red spots repre-
sent upregulated gene transcripts while green spots represent downregulated gene transcripts upon infection of cells with 
MHV. The dashed lines indicate the 2-fold change cut-off.BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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tion of mRNAs from the samples treated with the MHV-
specific oligo's confirmed the removal of the vRNAs from
the total RNA pool as judged from the almost complete
absence of the aberrant peaks in the Bioanalyzer profiles
(Fig. 4A; compare to Fig. 2B). Importantly, the vRNA cap-
ture procedure did not appear to affect the Bioanalzyer
mRNA amplification plots of the mock-infected cells
(data not shown). Next, the effect of the vRNA-depletion
on the microarray performance was studied. Thus, micro-
array analysis was performed as described above except
that the target samples, derived from both infected and
mock-infected cells, were treated with the MHV-specific
biotinylated oligo's. The results are shown in Fig. 4B. As is
evident from the scatter plot, the number of apparently
upregulated transcripts was greatly reduced. Increased
expression of almost 1800 genes was no longer detected
after vRNA depletion when compared to the standard
approach (Fig. 4C, and compare scatter plots shown in
Fig. 4B and Fig. 2B). This result is consistent with the
notion that vRNAs can hybridize to specific sequences on
the arrays. Thus, removal of vRNAs results in a significant
reduction of the number of false positive hits. 260 genes
were identified under both conditions. This set of genes is
likely to contain several hits that are still the result of
cross-hybridization, since vRNA depletion was not 100%.
For example, Usp2 and Figla, two highly upregulated
genes, the differential expression of which could not be
confirmed by quantitative RT-PCR, were still present
within this collection of genes, although the transcrip-
tional upregulation of these genes as judged from the
microarray experiment was much less pronounced (see
Additional file 1; False-positive hits). 40 genes out of these
260 hits were not detected in the experiment with ActD,
indicating that these genes are specifically upregulated at
Cross-hybridization of vRNA to array specific sequences Figure 3
Cross-hybridization of vRNA to array specific sequences. LR7 cells were either mock-infected or infected with MHV 
(MOI 10). The cells were incubated with ActD (20 μg/ml) 1 h prior to infection, and maintained in the presence of this drug 
throughout the experiment. Total RNA was isolated from mock- or MHV-infected cells at 6 h p.i. (A) A representative mRNA 
amplification plot of a total RNA sample derived from MHV-infected, ActD-treated cells at 6 h p.i. The arrow indicates the 
marker peak. (B) The scatter plot displays the average expression values from independent dye-swap hybridizations (n = 6) for 
each gene present on the arrays as described in legend of Fig.2. (C) The Venn diagram shows a comparison between the exper-
iments in the absence or presence of ActD.BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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the transcriptional level upon infection of cells with MHV.
Some of these genes were validated by quantitative RT-
PCR (see Additional file 1) and have already been
described elsewhere [7]. Interestingly, transcriptional
upregulation of 26 genes could only be detected with the
microarray experiment after removal of the vRNA. For
some of these genes, we confirmed their differential
expression by quantitative RT-PCR (see Additional file 1;
Additional hits).
We also compared the number of downregulated tran-
scripts in absence or presence of the vRNA capture proce-
dure. The majority of identified genes overlapped (n =
703) between both procedures, and downregulation of
several transcripts was confirmed by quantitative RT-PCR
vRNA depletion improves microarray analysis Figure 4
vRNA depletion improves microarray analysis. Total RNA samples were obtained from mock- and MHV-infected LR7 
cells at 6 h p.i. were subjected to the vRNA depletion protocol as detailed in the Materials and methods section. (A) Amplifica-
tion of the mRNA was monitored by analyzing the cRNA samples with a Bioanalyzer. A representative mRNA amplification 
plot of a total RNA sample derived from MHV-infected cells at 6 h p.i. after vRNA removal is shown. The arrow indicates the 
marker peak. (B) Total RNA samples were treated with the biotinylated oligo's (indicated as vRNA depleted) and were proc-
essed for microarray analysis as described in the Methods section. The scatter plots display the average expression values from 
independent dye-swap hybridizations (n = 6) for each gene present on the arrays as described in legend of Fig.2. (C) The Venn 
diagrams show a comparison between the experiments with and without vRNA depletion.BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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[7]. However, more downregulated transcripts were iden-
tified with the standard method (in the presence of vRNA)
than with the vRNA depletion approach, 1055 versus 806
genes, respectively (Fig. 4C). Downregulation of 352 tran-
scripts was specifically detected with standard method,
while 103 genes were exclusively detected with the new
approach. The reduced number of downregulated tran-
scripts after removal of the vRNAs is likely caused by the
normalization procedure, which relies on the assumption
that the bulk of genes are not differentially expressed
between samples [19]. Thus, a large number of false-posi-
tive hits, caused by cross-hybridization of vRNAs, will
result in an overrepresentation of downregulated tran-
scripts.
Although we cannot completely exclude that the oligo
capture procedure, besides vRNAs, also extracts some cel-
lular mRNAs, it is obvious that this method improves the
accuracy and sensitivity of the array analysis significantly.
First, the number of false positive hits reduced dramati-
cally, making follow-up analyses much easier to perform.
Secondly, the improved microarray approach allowed the
additional detection of several differentially expressed
genes, which are potentially important targets for further
research.
vRNA extraction improves Affymetrix microarray 
performance
Next we analyzed whether the removal of vRNA also
improves the performance using another array platform.
To this end, we used the commonly used Affymetrix Gene-
Chips® Mouse Genome 430 2.0 arrays. The same RNA
samples, previously used for the experiments with the 70-
mer oligonucleotide arrays, were now processed for anal-
ysis on the Affymetrix arrays as described in the Methods
section. Using GeneChips®, the standard method detected
the upregulation of 144 transcripts upon MHV infection,
whereas the vRNA capture procedure resulted in the iden-
tification of 241 upregulated transcripts, 133 of which
were only detected after vRNA depletion (Fig. 5A). The
differential expression of some of these genes, which
could only be detected after vRNA removal, was validated
by quantitative RT-PCR (see Additional file 1; Additional
hits). Both with the standard as with the vRNA depletion
method, 308 downregulated transcripts were identified.
198 genes were excluded from detection by vRNA deple-
tion, whereas 52 genes were specifically downregulated by
using this approach. Although the problem of cross-
hybridization (i.e. false-positive hits) that was observed
with the 70-mer oligonucleotide arrays did not become
apparent with the Affymetrix arrays, we could clearly
observe an improved microarray performance with the
Affymetrix arrays. Not only were more genes identified,
the expression of which was induced upon infection, also
the fold changes were found to be increased after vRNA
clearance. This phenomenon was also observed in the
experiments with the 70-mer oligonucleotide arrays.
Thus, when the expression levels of the genes, identified
by both array platforms using the vRNA depletion
method (n = 25), were compared to the expression levels
in the experiments without vRNA depletion, a significant
increase in the fold changes was observed on both array
platforms (Fig. 5B). The differential expression of some of
these genes was validated by using quantitative RT-PCR
(see Additional file 1; Hits by both platforms and both
methods). Note that this observation also holds true for
most other upregulated transcripts that were detected with
only one array platform (data not shown). Conclusively,
these results show that the removal of abundant 'contam-
inating' vRNAs in our CoV system enhanced the ability to
detect differential expression of host mRNA using micro-
array technology.
Discussion
Since microarray technology at the present has progressed
towards a point where technical variation, background
noise, and a lack of accuracy have greatly improved, the
critical step has moved towards the preparation of the
RNA sample. Non-specific hybridization is one of the
problems that can frequently occur, especially when there
is partial degradation of the RNA [20]. In addition, high
amounts of 'contaminating' RNA are likely to add to this
problem and to interfere with microarray analysis. Espe-
cially in RNA samples derived from virus-infected cells
where high amounts of a limited number of 'contaminat-
ing' RNAs are to be expected. In the case of coronaviruses,
replication and transcription results in the formation of a
nested set of subgenomic mRNAs that are 5' capped and
3' polyadenylated (Fig. 1). In time, the amount of corona-
virus vRNA increases exponentially. Most microarray pro-
tocols use mRNA amplification, which also results in
amplification of coronavirus RNAs. Indeed, at 6 h post
infection, substantial aberrant peaks were observed, when
the amplified mRNAs were analyzed with the Bioanalyzer.
The presence of high levels of MHV vRNA affected the
microarray analyses, depending on the microarray plat-
form used. On the one hand, the high amounts of vRNA
were shown to result in a large number of false-positive
hits probably as a result of mishybridization of vRNAs
with specific oligonucleotides of the 70-mer oligonucle-
otide arrays. Indeed, small stretches (10–15 nt) of homol-
ogous sequences were observed between vRNAs and the
oligonucleotides corresponding with the false-positive
hits. On the other hand, the same high number of false
positive hits was not observed with the Affymetrix arrays,
which contain multiple, much shorter, oligonucleotides
per gene. Long nucleotide probes, rather than short (25-
mers and shorter), demonstrate less non-specific binding,
as is often observed when partially degraded RNA samples BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
Page 8 of 12
(page number not for citation purposes)
are used, due to better hybridization and wash stringency
[20]. More importantly, however, Affymetrix GeneChips®
expression values are calculated by analyzing at least 11
different probes that anneal to the 3' end of each target
transcript. Thus, cross-hybridization of vRNA to only one
of these probes may not result in an over-estimation of
induced gene expression, and will be considered an out-
vRNA depletion increases sensitivity on different microarray platforms Figure 5
vRNA depletion increases sensitivity on different microarray platforms. (A) Affymetrix arrays were hybridized inde-
pendently with the same target samples (t = 6 h p.i.; treated with or without vRNA depletion) as described for the 70-mer oli-
gonucleotide arrays. Data analysis was performed as described in the Methods section. The Venn diagram depicts the 
comparison of the number of upregulated and, separately, the downregulated genes in the two experimental settings (with and 
without (standard) vRNA depletion). (B) The Venn diagram shows a comparison of the upregulated transcripts obtained with 
both the 70-mer arrays and the Affymetrix arrays using the vRNA depletion method. The genes within the intersection (n = 
25) were selected and the fold changes in gene expression, as discovered by each array analysis, for both methods (standard 
versus vRNA depleted) are plotted in the graph. Note that the induced expression of several of these genes was validated by 
quantitative RT-PCR (see Additional file 1). A paired t-test was performed to show the significant difference between both 
methods for each platform.BMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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lier. However, also for the Affymetrix arrays, the capture
and removal of the 'contaminating' vRNAs clearly
increased the sensitivity and accuracy of the microarray
experiments. Removal of vRNA lowered the threshold for
the detection of differentially transcribed genes, thereby
identifying potentially important genes for the under-
standing of virus-host interactions.
MHV-A59 vRNAs were removed from the total RNA sam-
ples using the GlobinClear kit (Ambion) with the use of
an alternative oligo capture mix, containing three 5' bioti-
nylated oligo's that are complementary to either the 5'
leader sequence, the N gene, or the 3' UTR of the MHV-
A59 genome. With each of the three oligo's we could tar-
get all vRNAs produced in an MHV-infected cell (Fig. 1),
resulting in a 90% reduction of vRNA present in the total
RNA sample. Care was taken in the design of the oligos in
order to minimize removal of cellular RNAs. However, the
procedure may be optimized further by using alternative
capture oligos. This method proved to be better than a
Rnase H digestion protocol, in which we tried to remove
the poly(A) tail from the vRNAs specifically by using the
MHV-specific oligo targeting the 3'UTR. RNAse H would
digest vRNA bound to the DNA oligo, thereby preventing
subsequent vRNA amplification during cRNA synthesis.
Although we could indeed see some improvement of the
microarray performance after RNase H digestion (data not
shown), the improvement was less pronounced com-
pared to direct vRNA removal using the GlobinClear sys-
tem.
The GlobinClear kit has been designed to remove globin
mRNAs from total blood RNA samples. Expression array
data generated from whole blood total RNA samples are
commonly known to have reduced detection sensitivity
compared to data from fractionated blood samples [21].
This is mainly caused by the fact that globin mRNA con-
stitutes a large fraction (up to 70%) of the total RNA pool,
since globin mRNA is highly expressed in red blood cells
and reticulocytes. Microarray analysis has shown that the
high amounts of globin mRNA transcripts resulted in
decreased sensitivity and increased variation. Similarly,
depletion of these abundant 'contaminating' transcripts
from the whole blood total RNA samples also resulted in
increased sensitivity [22-25]. This observed increase in
detection sensitivity after targeted RNA depletion could
well be a result of decreased competition between the
abundant RNA and cellular mRNA for access to the ampli-
fication reagents. Removal of these "contaminating"
RNAs will than lead to an increased labeling of host
mRNAs, which is detectable by microarray hybridizations.
In our experiments, the quality assessment metrics of the
affymetrix arrays indeed showed an increase in the
number of detected probe sets after vRNA depletion (see
Additional file 2).
High levels of 'contaminating' vRNAs, are not only
expected in RNA samples derived from coronavirus-
infected cells, but also from cells infected with other RNA
viruses. For flaviviruses, the vRNAs of which do not con-
tain polyadenylated 3'UTRs, mRNA amplification with
oligo(dT) primers should be sufficient to diminish the
effect of vRNAs on microarray performance. However, the
mRNAs synthesized by most other RNA viruses contain
poly(A) tails. In case of picorna- or alphaviruses, infection
results in the rapid production of high amounts of only 1
or 2 species of polyadenlyated vRNAs [5,6]. Therefore,
only a limited set of oligo's is likely to be required to
remove these transcripts from total RNA samples by
means of the oligo-capture procedure. For orthomyxovi-
ruses, which contain segmented RNA genomes from
which different polyadenylated vRNAs are produced [26],
a set of oligonucleotides will be required to eliminate all
vRNA species. It will be of interest to investigate whether
microarray expression profiling studies performed with
RNA samples derived from cells infected with other
viruses also benefit from the removal of vRNAs.
Conclusion
In this study we show that the presence of abundant viral
RNAs interferes with microarray gene expression profil-
ing, affecting both the accuracy and sensitivity of the pro-
cedure. Targeted removal of vRNA improved the
microarray analyses significantly on different array plat-
forms.
Methods
Cells and viruses
LR7 mouse fibroblast cells [27] were maintained in Dul-
becco's Modified Eagle's Medium (DMEM) (Cambrex Bio
Science) containing 10% (v/v) fetal calf serum (Bodinco
B.V.), 100 U/ml Penicillin, and 100 μg/ml Streptomycin,
supplemented with Geneticin G418 (250 μg/ml). MHV
strain A59 was grown in and titrated on LR7 cells.
MHV infection and total RNA isolation
LR7 cells were inoculated with MHV-A59 at a multiplicity
of infection (MOI) of 10 TCID50 (50% tissue culture infec-
tious doses) per cell, in phosphate buffered saline (PBS)
containing 50 μg/ml diethylaminoethyl-dextran (PBS-
DEAE). When indicated, the cells were incubated with 20
μg/ml of Actinomycin D (ActD; Sigma-Aldrich) from 1 h
prior to infection and maintained in the presence of this
drug throughout the experiment. After a 1 h inoculation,
the cells were washed and the culture medium was
replaced by complete DMEM. One hour later, at 2 h post
infection (p.i.), the fusion inhibitory mHR2 peptide (1
μM) was added to the culture medium to inhibit cell-to-
cell fusion [28]. Total RNA was isolated from mock or
MHV-A59 infected cells at the indicated time p.i. using the
TRIzol reagent (Invitrogen). RNA was further purifiedBMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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using the RNeasy mini-kit with subsequent DNaseI treat-
ment on the column (Qiagen). RNA concentration and
integrity were determined by spectrometry and by a
microfluidics-based platform using a UV-mini1240
device (Shimadzu) and a 2100 Bioanalyzer (Agilent Tech-
nologies), respectively.
vRNA extraction
MHV-A59 vRNA was removed from the total RNA sam-
ples using the GlobinClear kit (Ambion Inc.) with the use
of an alternative oligo capture mix that contained three 5'
biotinylated oligo's, complementary to the 5' leader
sequence, the nucleocapsid (N) gene and the 3'untrans-
lated region (UTR) of the MHV-A59 genome. All subse-
quent steps were performed according to the
manufacturer's protocol. After purification, RNA integrity
was analyzed as described above. The sequences of the
vRNA capture oligo's are listed in Table 1, and the loca-
tions of the complementary sequences in the MHV-A59
genome are depicted in Fig. 1.
cRNA synthesis, labeling, and hybridization onto 
microarrays
70-mer oligonucleotide arrays
mRNA was amplified from 1 μg of total RNA by cDNA
synthesis with oligo(dT) double-anchored primers, fol-
lowed by in vitro transcription using Amino Allyl Mes-
sageAmp™ II kit (Ambion) as described previously [29].
During transcription, 5-(3-aminoallyl)-UTP was incorpo-
rated into the single stranded cRNA. Cy3 and Cy5 NHS-
esters (Amersham Biosciences) were coupled to 2 μg
cRNA. RNA quality was monitored after each successive
step using the methods described above. A Mouse Array-
Ready Oligo set (version 3.0) was purchased (Operon)
and printed on Corning UltraGAPS slides. Mouse slides
containing 35,000 spots (32,101 70-mer oligonucle-
otides, and 2,891 control spots) were hybridized with 1
μg of each alternatively labeled cRNA target at 42°C for
16–20 h using LifterSlips (Erie Scientific) and Corning
Hybridization Chambers [30]. After hybridization the
slides were washed extensively and scanned using the Agi-
lent G2565AA DNA Microarray Scanner.
Affymetrix arrays
mRNA amplification was performed using the Mes-
sageAmp™ II Biotin Enhanced kit from Ambion, according
to the manufacturer's instructions. Briefly, first-strand
cDNA was synthesized by a reverse transcription reaction
with T7 oligo(dT) primers. Second-strand cDNA was syn-
thesized with the DNA polymerase mix supplied by the kit
to provide double-stranded DNA template for in vitro
transcription. Biotinylated amplified cRNA was produced
by T7 RNA polymerase, after which the cRNA targets were
hybridized to Mouse Genome 430 2.0 arrays (Affymetrix,
Santa Clara, USA). After extensive washing and subse-
quent staining, the arrays were scanned using an Affyme-
trix Genechip® Scanner 3000. All steps were performed as
recommended by the manufacturer.
Microarray data analysis
70-mer oligonucleotide arrays
Images were quantified and background corrected using
Imagene 5.6 software. The data were normalized using
Lowess print-tip normalization as described previously
[19]. To identify the genes that were significantly different
within each experiment, a one-class Significance Analysis
of Microrarrays (SAM) [31] was performed on the average
of independent dye-swap hybridizations (n = 6), using a
false discovery rate (FDR) of 1%. To increase the confi-
dence level, a cut-off at a 2-fold change in expression was
applied. The data were subjected to Genespring 7.2 soft-
ware (Agilent Technologies) for further analysis.
Affymetrix arrays
Images were quantified with Affymetrix Microarray Suite
5.0 (MAS 5.0) software. Quality control (QC) metrics for
all arrays are provided as an additional file (see Additional
file 2). The robust multichip average (RMA) method [32]
was used to process all arrays as a single experiment. A 2-
Way ANOVA was used to identify genes that were differ-
entially expressed under the different experimental condi-
tions. The FDR was controlled at 5% using the Benjamini-
Hochberg (BH) step-up procedure [33]. To increase the
confidence level, a cut-off at a 2-fold change in expression
was applied. Hierarchical clustering was performed using
average linkage clustering with Euclidean Distance. All
analyses were performed using Partek® GS software (Cop-
yright, Partek Inc.).
ArrayExpress accession numbers
MIAME-compliant data in MAGE-ML format has been
submitted to the public microarray database ArrayExpress
[34]. Note that the array data obtained from both plat-
forms are submitted as a single experiment. Accession
Table 1: vRNA capture mix.
# Oligonucleotide sequences (5'to 3') Locations of complementary nucleotides within the MHV-A59 genome
A Biotin-CTACAAGAGTTTTAGAGTTGAGAGGGTACG 24–53; 5'Leader
B Biotin-GCACTACGCCATCATCAAGGATCTGAG 30975–31002; N gene
C Biotin-GGACCTTGCTAACTTCTCTCACACATTCTC 31187–31216; 3'UTRBMC Genomics 2008, 9:221 http://www.biomedcentral.com/1471-2164/9/221
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numbers: array designs, A-UMCU-7 and A-AFFY-45; and
gene expression data of MHV-infected LR7 cells, E-MEXP-
1373. Also included are complete descriptions of proto-
cols for total RNA isolation and mRNA amplification, P-
MEXP-34397; vRNA depletion, P-MEXP-114798; cRNA
labeling, P-MEXP-34400, P-MEXP-35534, P-MEXP-8712;
array hybridization and washing of slides, P-MEXP-
34401, P-AFFY-6; scanning of slides, P-MEXP-34430; and
data normalization, P-MEXP-34431, P-MEXP-120375.
Quantitative RT-PCR
Altered mRNA expression levels of several genes, which
were identified by microarray analysis, were verified by
quantitative reverse transcription (RT)-PCR using Taq-
Man®  Gene Expression assays (Applied Biosystems),
according to the manufacturer's instructions. Note that
from the different groups shown in Additional file 1 (i.e.
false positive hits, additional hits, and hits by both plat-
forms and both methods) genes were randomly selected
for RT-PCR validation. Reactions were performed using an
ABI Prism 7000 sequence detection system. The compara-
tive Ct-method was used to determine the fold change for
each individual gene. The housekeeping gene GAPDH was
used as a reference in all experiments. The amounts of
viral genomic and subgenomic RNA were determined by
quantitative RT-PCR as described previously [35,36].
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